SI1594517T1 - Sestavki za zdravljenje gastrointestinalnih motenj - Google Patents

Sestavki za zdravljenje gastrointestinalnih motenj

Info

Publication number
SI1594517T1
SI1594517T1 SI200430401T SI200430401T SI1594517T1 SI 1594517 T1 SI1594517 T1 SI 1594517T1 SI 200430401 T SI200430401 T SI 200430401T SI 200430401 T SI200430401 T SI 200430401T SI 1594517 T1 SI1594517 T1 SI 1594517T1
Authority
SI
Slovenia
Prior art keywords
disorders
constipation
conditions
dyspepsia
functional
Prior art date
Application number
SI200430401T
Other languages
English (en)
Inventor
Mark G Currie
Shalina Mahajan-Miklos
G Todd Milne
Thea Norman
Original Assignee
Microbia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32854294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1594517(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Microbia Inc filed Critical Microbia Inc
Publication of SI1594517T1 publication Critical patent/SI1594517T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
SI200430401T 2003-01-28 2004-01-28 Sestavki za zdravljenje gastrointestinalnih motenj SI1594517T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44309803P 2003-01-28 2003-01-28
US47128803P 2003-05-15 2003-05-15
US51946003P 2003-11-12 2003-11-12
EP04706011A EP1594517B1 (en) 2003-01-28 2004-01-28 Compositions for the treatment of gastrointestinal disorders
PCT/US2004/002390 WO2004069165A2 (en) 2003-01-28 2004-01-28 Methods and compositions for the treatment of gastrointestinal disorders

Publications (1)

Publication Number Publication Date
SI1594517T1 true SI1594517T1 (sl) 2007-10-31

Family

ID=32854294

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200430401T SI1594517T1 (sl) 2003-01-28 2004-01-28 Sestavki za zdravljenje gastrointestinalnih motenj
SI200431521T SI1911763T1 (sl) 2003-01-28 2004-01-28 Sestavki za zdravljenje gastrointestinalnih motenj
SI200431918T SI2246360T1 (sl) 2003-01-28 2004-01-28 Sestavki za zdravljenje gastrointestinalnih motenj

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200431521T SI1911763T1 (sl) 2003-01-28 2004-01-28 Sestavki za zdravljenje gastrointestinalnih motenj
SI200431918T SI2246360T1 (sl) 2003-01-28 2004-01-28 Sestavki za zdravljenje gastrointestinalnih motenj

Country Status (29)

Country Link
US (3) US20040266989A1 (sl)
EP (3) EP2246360B1 (sl)
JP (3) JP4584911B2 (sl)
KR (2) KR101227626B1 (sl)
CN (2) CN101787073B (sl)
AT (2) ATE365174T1 (sl)
AU (2) AU2004210161B2 (sl)
BE (1) BE2013C032I2 (sl)
BR (2) BR122018074353B8 (sl)
CA (1) CA2514507C (sl)
CY (5) CY1110905T1 (sl)
DE (2) DE602004028678D1 (sl)
DK (3) DK2246360T3 (sl)
ES (3) ES2285417T3 (sl)
FR (2) FR13C0029I2 (sl)
HK (1) HK1078768A1 (sl)
HU (1) HUS1300022I1 (sl)
IL (2) IL169863A (sl)
LT (1) LTC1594517I2 (sl)
LU (2) LU92200I2 (sl)
MX (1) MXPA05008097A (sl)
NL (1) NL300593I2 (sl)
NO (2) NO334112B1 (sl)
NZ (2) NZ570134A (sl)
PT (3) PT1594517E (sl)
RU (2) RU2353383C2 (sl)
SG (2) SG192300A1 (sl)
SI (3) SI1594517T1 (sl)
WO (1) WO2004069165A2 (sl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539132T3 (es) 2001-03-29 2015-06-26 Synergy Pharmaceuticals, Inc. Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004028678D1 (de) * 2003-01-28 2010-09-23 Ironwood Pharmaceuticals Inc Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
PT1644021E (pt) 2003-06-13 2013-01-30 Ironwood Pharmaceuticals Inc Métodos e composições para o tratamento de distúrbios gastrointestinais
US20050266028A1 (en) * 2004-05-25 2005-12-01 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating an immune response
EP1813271A4 (en) * 2004-10-26 2008-05-21 Ajinomoto Kk PREVENTIVE / THERAPEUTIC AGENT FOR VISCERAL PAIN
CA2619650A1 (en) * 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2625447C (en) 2005-09-29 2015-06-09 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Compositions and methods for stimulating gastrointestinal motility
WO2007101161A2 (en) * 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2650303A1 (en) * 2007-02-26 2013-10-16 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
WO2008137318A1 (en) * 2007-05-04 2008-11-13 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating disorders associated with salt or fluid retention
US8969514B2 (en) * 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009256156B2 (en) 2008-06-04 2014-09-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010005515A2 (en) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Protein expression methods
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
SI2328601T1 (sl) * 2008-08-15 2020-08-31 Ironwood Pharmaceuticals, Inc. Linaklotid vsebujoče formulacije za oralno dajanje
CA2743172A1 (en) 2008-11-19 2010-05-27 Forest Laboratories Holdings Limited Crystalline form of linaclotide
AU2009322285B2 (en) * 2008-12-03 2016-07-28 Bausch Health Ireland Limited Formulations of guanylate cyclase C agonists and methods of use
EP2417152B1 (en) 2009-04-10 2013-10-02 Corden Pharma Colorado, Inc. Process for isolating linaclotide
WO2011017502A2 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
RU2012109415A (ru) 2009-08-13 2013-09-20 Айронвуд Фармасьютикалз, Инк. Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы
WO2011057272A1 (en) 2009-11-09 2011-05-12 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
KR20120103689A (ko) * 2009-12-07 2012-09-19 아이언우드 파마슈티컬스, 인코포레이티드 위장 장애의 치료
WO2011103311A2 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
WO2011156453A2 (en) 2010-06-09 2011-12-15 Combimab, Inc. Therapeutic peptides
CA2808091C (en) 2010-08-11 2019-05-21 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2810243C (en) 2010-09-15 2021-04-20 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2012155114A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Peptides derived from uroguanylin and their use in gastrointestinal disorders
CA2835624A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
MD480Z (en) * 2011-07-07 2012-09-30 Elvira Andon Method for treating acute ulcerative nonspecific colitis
WO2013025969A1 (en) 2011-08-17 2013-02-21 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
RU2528641C2 (ru) * 2012-08-22 2014-09-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных с синдромом диспепсии в сочетании с избыточной массой тела
CN102875655B (zh) * 2012-09-29 2014-12-17 深圳翰宇药业股份有限公司 一种合成利那洛肽的方法
EP2950803A1 (en) 2013-01-30 2015-12-09 Sandoz AG Crystalline form of linaclotide
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN105979959B (zh) 2013-08-09 2021-11-30 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
ES2947591T3 (es) * 2015-05-01 2023-08-11 Ironwood Pharmaceuticals Inc Composiciones para la limpieza del colon y el tratamiento de trastornos gastrointestinales
EP3430056A4 (en) * 2016-03-15 2019-11-20 The Regents of the University of California METHOD AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF ALPHA-8-BETA-1-INTEGRIN ASSOCIATED DISEASES
CN107929718A (zh) * 2017-10-19 2018-04-20 南京星银药业集团有限公司 Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法
JP2022503807A (ja) * 2018-10-23 2022-01-12 エービーケー バイオメディカル インコーポレイテッド 輸送装置
CN109467606A (zh) * 2018-11-15 2019-03-15 大连理工大学 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
RU2712761C1 (ru) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
CN111265653B (zh) * 2020-02-09 2023-05-09 华中科技大学同济医学院附属协和医院 心房利钠肽在制备炎症性肠病治疗药物中的应用
US20230035733A1 (en) * 2020-03-26 2023-02-02 Dusa Pharmaceuticals, Inc. Management of dermal neurofibromatosis lesions
WO2023144292A1 (en) 2022-01-28 2023-08-03 Fresenius Kabi Ipsum S.R.L. Process for the preparation of linaclotide

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US73628A (en) * 1868-01-21 mitchell
US152868A (en) * 1874-07-07 Improvement in type-setting machines
US258687A (en) * 1882-05-30 Grain-binder
US32684A (en) * 1861-07-02 Stump-extkactob
US232013A (en) * 1880-09-07 Henry h
US121961A (en) * 1871-12-19 Improvement in devices for supporting pipe-cores
US266989A (en) * 1882-11-07 Automatic fire
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
IT1217123B (it) 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (sl) 1989-07-28 1992-01-15 Debiopharm Sa
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (fr) 1991-04-02 1994-12-23 Logeais Labor Jacques Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5140102A (en) 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
RU2194760C2 (ru) * 1991-12-02 2002-12-20 Кор Терапьютикс, Инк. Иммуноглобулиновый полипептид, его фрагмент, композиция, штамм гибридных культивируемых клеток, способ получения полипептида
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
DE69225499T2 (de) 1991-12-30 1999-02-04 Neurex Corp Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
AU680650B2 (en) 1993-01-06 1997-08-07 Ipsen Manufacturing Ireland Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5395490A (en) * 1993-05-14 1995-03-07 Intertec, Ltd. Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies
EP0734264B1 (en) * 1993-10-26 2004-02-18 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US5489670A (en) * 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
DK0835126T3 (da) 1995-06-27 2003-07-14 Elan Pharm Inc Sammensætninger og formuleringer til fremstilling af analgesimidler og til hamning af fremadskridende neuropatiske amertelidelser
AP9801237A0 (en) 1995-11-24 1998-06-30 Smithkline Beecham Farm S P A Quinoline derivatives.
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
CA2250981C (en) 1996-04-23 2002-07-02 Kinerton Limited Acidic polylactic polymers
US6589750B2 (en) 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
US6333354B1 (en) 1997-02-28 2001-12-25 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
JP2001516765A (ja) 1997-09-12 2001-10-02 ヴォルフ ゲオルグ フォースマン 真性糖尿病及び肥満の治療のための組成物
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
IT1304152B1 (it) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
EP1185294B1 (en) 1999-06-23 2005-03-30 Institut Pasteur Peptides for the treatment of impaired interpersonal and behavioral disorders
EP1204429B1 (en) 1999-08-18 2003-10-29 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide
SE9903291D0 (sv) 1999-09-15 1999-09-15 Astra Ab New process
JP2003516316A (ja) 1999-10-06 2003-05-13 ファルマシア コーポレイション 腸癌阻止剤としてのウログアニリン
WO2001032180A2 (en) 1999-11-01 2001-05-10 Rodeva Limited Composition for treatment of constipation and irritable bowel syndrome
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
AU3580001A (en) 2000-03-01 2001-09-12 University College London Modulators of the endocannabinoid uptake and of the vallinoid receptors
PT1216707E (pt) 2000-12-22 2005-06-30 Pasteur Institut Novas utilizacoes terapeuticas para um smr-1-peptideo
JP2004521123A (ja) 2001-02-02 2004-07-15 ファルマシア・コーポレーション 腸癌阻害のためのウログアニリンおよびシクロオキシゲナーゼ−２阻害薬の組合わせ
ES2539132T3 (es) * 2001-03-29 2015-06-26 Synergy Pharmaceuticals, Inc. Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis
AU2002311556A1 (en) 2001-03-30 2002-10-15 University Of Copenhagen Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
WO2002098912A2 (de) * 2001-06-05 2002-12-12 Yalcin Cetin Luftseitig verabreichte guanylat cyclase c liganden für atemwegserkrankungen
FR2830451B1 (fr) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
US20040121961A1 (en) 2002-02-04 2004-06-24 Jaime Masferrer Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
AU2003224644A1 (en) 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
JP2005526079A (ja) 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
DE60327315D1 (de) 2002-05-17 2009-06-04 Tioga Pharmaceuticals Inc Verwendung von verbindungen, die als selektive opiat-rezeptor-modulatoren wirksam sind
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
DE602004028678D1 (de) 2003-01-28 2010-09-23 Ironwood Pharmaceuticals Inc Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8206704B2 (en) 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
CA2619650A1 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
CN101787073A (zh) 2010-07-28
RU2353383C2 (ru) 2009-04-27
EP2246360B1 (en) 2012-06-27
LTC1594517I2 (lt) 2020-03-10
DK2246360T3 (da) 2012-08-13
CY2013021I1 (el) 2020-05-29
BRPI0407071B8 (pt) 2021-05-25
NO336768B1 (no) 2015-11-02
JP4584911B2 (ja) 2010-11-24
SI1911763T1 (sl) 2010-11-30
ATE365174T1 (de) 2007-07-15
EP1594517A2 (en) 2005-11-16
NO20053864L (no) 2005-10-26
RU2543350C2 (ru) 2015-02-27
CN101787073B (zh) 2013-12-25
CN100589839C (zh) 2010-02-17
AU2004210161A1 (en) 2004-08-19
NO20053864D0 (no) 2005-08-18
EP1594517B1 (en) 2007-06-20
US20110124583A1 (en) 2011-05-26
CY2013022I1 (el) 2020-05-29
EP1911763A3 (en) 2008-06-25
EP1911763A2 (en) 2008-04-16
ES2285417T3 (es) 2007-11-16
DK1911763T3 (da) 2010-11-15
HK1078768A1 (en) 2006-03-24
BR122018074353B1 (pt) 2019-07-16
RU2014153593A3 (sl) 2018-08-06
ATE477268T1 (de) 2010-08-15
JP2010222377A (ja) 2010-10-07
EP2246360A1 (en) 2010-11-03
DE602004007105D1 (de) 2007-08-02
AU2004210161B2 (en) 2009-11-26
RU2008147983A (ru) 2010-06-10
NL300593I1 (nl) 2015-10-21
US20090005534A1 (en) 2009-01-01
NZ541595A (en) 2008-08-29
WO2004069165A3 (en) 2005-03-17
ES2387848T3 (es) 2012-10-02
KR20050106404A (ko) 2005-11-09
PT1911763E (pt) 2010-11-18
JP5563384B2 (ja) 2014-07-30
US20040266989A1 (en) 2004-12-30
JP2006516631A (ja) 2006-07-06
CA2514507A1 (en) 2004-08-19
PT1594517E (pt) 2007-07-20
NO334112B1 (no) 2013-12-09
LU92201I2 (fr) 2013-11-22
JP2013116910A (ja) 2013-06-13
US8080526B2 (en) 2011-12-20
LU92200I1 (fr) 2020-06-02
FR13C0030I1 (fr) 2013-07-05
CA2514507C (en) 2012-03-20
NZ570134A (en) 2010-02-26
RU2014153593A (ru) 2016-07-20
DK1594517T3 (da) 2007-10-29
SG168407A1 (en) 2011-02-28
LU92200I2 (fr) 2024-03-21
PT2246360E (pt) 2012-08-31
WO2004069165A2 (en) 2004-08-19
MXPA05008097A (es) 2006-02-08
DE602004028678D1 (de) 2010-09-23
CY1111058T1 (el) 2015-06-11
ES2350123T3 (es) 2011-01-18
SG192300A1 (en) 2013-08-30
AU2009235993A1 (en) 2009-11-26
NL300593I2 (nl) 2020-04-15
BRPI0407071A (pt) 2006-01-24
BR122018074353B8 (pt) 2023-05-02
DE602004007105T2 (de) 2008-02-28
IL221380A0 (en) 2012-09-24
RU2763796C2 (ru) 2022-01-11
JP5748791B2 (ja) 2015-07-15
FR13C0029I2 (fr) 2024-04-19
BRPI0407071B1 (pt) 2019-02-12
EP1911763B1 (en) 2010-08-11
KR101227627B1 (ko) 2013-01-31
KR20110114682A (ko) 2011-10-19
NO20130460L (no) 2005-10-26
AU2009235993B2 (en) 2013-07-04
CY1110905T1 (el) 2015-06-10
RU2005127058A (ru) 2006-03-10
CY1113217T1 (el) 2016-04-13
FR13C0029I1 (fr) 2013-07-05
US7704947B2 (en) 2010-04-27
SI2246360T1 (sl) 2012-10-30
BE2013C032I2 (sl) 2023-08-22
CN1795007A (zh) 2006-06-28
IL169863A (en) 2012-10-31
KR101227626B1 (ko) 2013-02-01
EP1594517A4 (en) 2006-03-29
HUS1300022I1 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
HUS1300022I1 (hu) Készítmények gasztrointesztinális rendellenességek kezelésére
SG153824A1 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2005016244A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2007022531A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2006086653A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2007101158A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2008002971A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2005074575A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
EA201290799A1 (ru) Лечение желудочно-кишечных расстройств
WO2007062168A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
WO2006102069A3 (en) Methods and compositions for the treatment of hypertension and gastrointestinal disorders
CY1113569T1 (el) Μεθοδοι και συνθεσεις για την αγωγη γαστρεντερικων διαταραχων